Your browser is no longer supported. Please, upgrade your browser.
Settings
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own4.80% Shs Outstand78.99M Perf Week-2.52%
Market Cap122.43M Forward P/E- EPS next Y-0.58 Insider Trans0.00% Shs Float65.95M Perf Month-3.13%
Income-59.80M PEG- EPS next Q-0.14 Inst Own32.90% Short Float19.29% Perf Quarter-17.11%
Sales13.40M P/S9.14 EPS this Y16.50% Inst Trans-5.48% Short Ratio18.97 Perf Half Y22.05%
Book/sh1.26 P/B1.23 EPS next Y-7.40% ROA-49.30% Target Price1.65 Perf Year-73.64%
Cash/sh1.10 P/C1.41 EPS next 5Y7.33% ROE-68.90% 52W Range1.20 - 8.22 Perf YTD0.00%
Dividend- P/FCF- EPS past 5Y-2.70% ROI-83.20% 52W High-81.14% Beta1.85
Dividend %- Quick Ratio3.30 Sales past 5Y-11.80% Gross Margin- 52W Low29.17% ATR0.12
Employees113 Current Ratio3.30 Sales Q/Q20439.30% Oper. Margin- RSI (14)46.01 Volatility11.05% 7.43%
OptionableYes Debt/Eq0.03 EPS Q/Q76.70% Profit Margin- Rel Volume13.57 Prev Close1.73
ShortableYes LT Debt/Eq0.03 EarningsMay 03 AMC Payout- Avg Volume670.67K Price1.55
Recom3.00 SMA20-3.40% SMA50-3.86% SMA200-49.46% Volume9,104,207 Change-10.40%
Nov-30-16Downgrade William Blair Outperform → Mkt Perform
Nov-30-16Downgrade Piper Jaffray Overweight → Neutral
Nov-30-16Downgrade Chardan Capital Markets Buy → Neutral $8 → $2
Nov-30-16Downgrade Cantor Fitzgerald Buy → Hold
Nov-10-16Reiterated Chardan Capital Markets Buy $10 → $8
Aug-18-16Initiated Cantor Fitzgerald Buy $15
May-19-16Initiated Chardan Capital Markets Buy $12
Sep-25-15Reiterated Piper Jaffray Overweight $12 → $20
Oct-09-14Downgrade RBC Capital Mkts Outperform → Sector Perform $35 → $9
Mar-05-14Initiated RBC Capital Mkts Outperform $35
Mar-05-14Initiated Deutsche Bank Buy $45
Feb-26-13Initiated Dawson James Buy $4
Jun-09-17 04:30PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
May-26-17 12:58PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 26, 2017 Capital Cube
May-16-17 12:46PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 16, 2017 Capital Cube
May-06-17 08:10PM  Edited Transcript of ARWR earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-05-17 03:50PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 5, 2017 Capital Cube
11:10AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017 Capital Cube
08:00AM  Today's Research Reports on Arrowhead Pharmaceuticals and Paratek Pharmaceuticals Post Earnings Accesswire
May-03-17 04:00PM  Arrowhead Reports Fiscal 2017 Second Quarter Results Business Wire
Apr-26-17 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results Business Wire
Apr-24-17 07:30AM  Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress Business Wire
Apr-20-17 11:30AM  Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress Business Wire
Apr-19-17 02:10PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : April 19, 2017 Capital Cube
Apr-05-17 07:30AM  Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress Business Wire
07:30AM  Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress
Mar-27-17 03:49PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
03:49PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : March 27, 2017
Mar-23-17 07:38AM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification
07:30AM  Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement Business Wire
Mar-21-17 11:32AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q1, 2017 By the Numbers : March 21, 2017 Capital Cube -7.11%
11:32AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q1, 2017 By the Numbers : March 21, 2017
Feb-27-17 10:00AM  SBPH: 2016 Results Sustaining Continued HBV/STING Development Zacks Small Cap Research +9.77%
10:00AM  SBPH: 2016 Results Sustaining Continued HBV/STING Development
Feb-16-17 01:34PM  These 5 Stocks Under $10 Could Explode Higher TheStreet.com
01:34PM  These 5 Stocks Under $10 Could Explode Higher
Feb-10-17 01:04PM  ARROWHEAD PHARMACEUTICALS, INC. Financials
Feb-06-17 05:42PM  Edited Transcript of ARWR earnings conference call or presentation 6-Feb-17 9:30pm GMT Thomson Reuters StreetEvents
05:42PM  Edited Transcript of ARWR earnings conference call or presentation 6-Feb-17 9:30pm GMT
04:15PM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
04:06PM  Arrowhead Research reports 1Q loss Associated Press
04:06PM  Arrowhead Research reports 1Q loss
04:00PM  Arrowhead Reports Fiscal 2017 First Quarter Results Business Wire
07:07AM  Q1 2017 Arrowhead Pharmaceuticals Inc Earnings Release - After Market Close
Feb-01-17 09:30AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on Arrowhead Pharmaceuticals and Jaguar Animal Health Accesswire -10.31%
Jan-30-17 04:01PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results Business Wire
Jan-20-17 07:51PM  Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action Business Wire
Jan-14-17 06:25PM  IMPORTANT ARWR SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Jan-13-17 05:41PM  SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Arrowhead Pharmaceuticals, Inc. and Certain Officers ARWR GlobeNewswire -5.07%
11:01AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 ARWR GlobeNewswire
Jan-12-17 11:00AM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:10AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) and Lead Plaintiff Deadline: January 16, 2017 GlobeNewswire
09:42AM  These 3 Biotech Stocks Are Already Moving Wildly on Thursday
Jan-10-17 10:51AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire +6.88%
Jan-09-17 12:27PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 ARWR Business Wire
09:50AM  Mondays 4 Biggest Biopharma Movers
04:06AM  Arrowhead Provides Response to New Minority Shareholder Announcement Business Wire
Jan-07-17 06:00AM  DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm Business Wire
Jan-06-17 04:45PM  ARWR LOSS NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ARWR GlobeNewswire +22.50%
Jan-05-17 05:25AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -5.33%
Jan-04-17 10:13AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) and Lead Plaintiff Deadline: January 16, 2017 Accesswire
Jan-03-17 03:22PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire +8.39%
12:30PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : January 3, 2017
11:26AM  ARWR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Arrowhead Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 Business Wire
Dec-28-16 11:37AM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:38AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) and Lead Plaintiff Deadline: January 16, 2017 Accesswire
Dec-27-16 02:22PM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
12:51PM  ARWR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of Commencement of a Class Action Involving Arrowhead Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 PR Newswire
Dec-23-16 06:20PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire +16.06%
04:42PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. - ARWR GlobeNewswire
02:00PM  Spring Bank (SBPH) Inks 3rd Collaboration Agreement
08:15AM  Post Earnings Coverage as Arrowhead Reported Annual Results; Announced Collaboration with Amgen Accesswire
Dec-21-16 12:14PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
11:59AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : December 21, 2016
10:40AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 Business Wire
Dec-20-16 05:48PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
04:05PM  Fitbit, Himax Drop into Tuesdays 52-Week Low Club at 24/7 Wall St.
02:20PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit ARWR GlobeNewswire
01:54PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
10:37AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) and Lead Plaintiff Deadline: January 16, 2017 Accesswire
Dec-19-16 04:28PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
02:56PM  Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Arrowhead Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
08:23AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: 2016 By the Numbers : December 19, 2016
Dec-16-16 12:20PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
09:56AM  ARWR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareholders of Commencement of a Class Action Involving Arrowhead Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 Business Wire
Dec-14-16 06:27PM  Edited Transcript of ARWR earnings conference call or presentation 14-Dec-16 9:30pm GMT
04:55PM  Arrowhead Research reports 4Q loss
04:06PM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
04:00PM  Arrowhead Reports Fiscal 2016 Year End Results Business Wire
07:07AM  Q4 2016 Arrowhead Pharmaceuticals Inc Earnings Release - After Market Close
Dec-13-16 01:41PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:37AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) & Lead Plaintiff Deadline: January 16, 2017 Accesswire
Dec-12-16 04:21PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire -5.19%
04:04PM  Ophthotech, Alexion Tumble into Mondays 52-Week Low Club at 24/7 Wall St.
11:02AM  ARWR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Arrowhead Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 GlobeNewswire
09:54AM  Here is What Hedge Funds Think About Arrowhead Pharmaceuticals Inc (ARWR) at Insider Monkey
Dec-08-16 08:08PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
07:12PM  ARWR NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ARWR Business Wire
Dec-07-16 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results Business Wire
01:28PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
11:25AM  EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 ARWR GlobeNewswire
Dec-05-16 12:57PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:10AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) & Lead Plaintiff Deadline: January 16, 2017 GlobeNewswire
Dec-04-16 01:04PM  7 of the Most Shocking Biotech Pipeline Blowups of 2016 at Motley Fool
Dec-02-16 09:43PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire +9.09%
08:52PM  INVESTOR ALERT: Stull, Stull & Brody Filed a Securities Class Action Lawsuit on Behalf of Purchasers of Arrowhead Pharmaceuticals, Inc. Common Stock and Encourages Shareholders with Losses to Contact the Firm GlobeNewswire
Dec-01-16 04:46PM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events -8.33%
11:15AM  Arrowhead Halts 3 Drug Projects, Axes Jobs (ARWR) at Investopedia
Nov-30-16 06:48PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -67.20%
04:45PM  The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Arrowhead Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
04:21PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
04:04PM  Arrowhead, Coca-Cola Lead Wednesdays 52-Week Low Club at 24/7 Wall St.
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GIVEN DOUGLAS BDirectorOct 14Sale6.7212,00080,64070,000Oct 18 07:53 PM
Myszkowski Kenneth AllenChief Financial OfficerAug 23Option Exercise2.016,90013,869122,589Aug 24 06:39 PM
Myszkowski Kenneth AllenChief Financial OfficerAug 23Sale8.006,90055,200115,689Aug 24 06:39 PM
Myszkowski Kenneth AllenChief Financial OfficerAug 22Option Exercise2.0113,10026,331128,789Aug 24 06:39 PM
Myszkowski Kenneth AllenChief Financial OfficerAug 22Sale8.0013,100104,800115,689Aug 24 06:39 PM
Anzalone Christopher RichardChief Executive OfficerJun 30Option Exercise5.0915,77280,2791,117,233Jul 05 06:11 PM